Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
mrmain, Until now - a good day for Amarin - not something we are experiencing often these days 🙂
JR. I get your point - but do not agree in your conclusion. There is big risk in investing 'big' in these undervalued Bio Companies.
Sarissa has specialized in doing so - and need to make money where ever they can - to cover the big risks they take. And once in a while one of their Investments fail - that's an inevitable part of the niche Bio market they opperate in.
----------------------
But unlike you I find it great (and our luck as buried investors) - that a company like Sarissa exists - with their experience in handling the uphill battle of where we are as Amarin investors.
I don't 'as you' see it as an opposite - that Sarissa works for its own investors - at the same time as they work to increase the value of the Bio Companies they invest in. It is two sides of the same coin - of working for succes of their business.
JR. Ok - text in quote 'is part of a general Sarissa document' - that states what I just said' - Sarissa is a Hedge Fund - and acts like One' - where is the problem ?
Thanks for the 'quick reply' 🙂
Tats, Would you please document precisely - from where in Sarissa documents you have your quote belov:
What Makes Amarin (AMRN) a New Buy Stock
https://finance.yahoo.com/news/makes-amarin-amrn-buy-stock-170004209.html
(just saw Invest83838 - put the same link here) 🙂
JohnC, Just before you go - would you please 'document' for all to see - your holding of 588.000 shares from your post below:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173343739
And please stop posting garbage on Sarissa - AD and Amarin also on other finance boards - thanks !
You be well 🙂
Lizzy, Thanks - encouraging 🙂
Here a little sunday entertainment:
Novo Nordisk - didn't become 2nd most valuarble company in EU - number 17 in the world - out of pure goodness to help humanity !
Under here a few links (translate with google) - about how aggressively the giant med company operate:
https://www.reuters.com/investigates/special-report/health-obesity-novonordisk-doctors/
https://www.bt.dk/samfund/medie-novo-har-brugt-millioner-paa-amerikanske-fedmelaeger-for-at-promovere
https://www.bt.dk/erhverv/novo-har-betalt-laeger-i-usa-for-promovering-af-vaegttabsmedicin
https://www.bt.dk/samfund/medicinkoebmaend-tjener-millioner-paa-medicinmangel-det-er-lidt-brutalt-det-der
https://medwatch.dk/Medicinal___Biotek/article16562978.ece
General search Novo articles media BT:
https://www.bt.dk/search?query=Novo
Zip - Agree - I also found the number surprisingly 'low' taken out of more than 15.000 people.
My point were - that even this big Pharma Company - mention this low number' in an important official press release - which indicates that Brav result 'could be taken serious' - even the number of patients is not very big 🙂
Laurent, The sheer size - success and power of Novo Nordisk - gives reason to believe that the project aimed at AZ has been thoroughly investigated before they go public with this announcement.
I noticed at one point numbers mentioned - that equals Brave. So maybe' - If the results (taken they show real benefit in preventing dementia/AZ) will be sufficient seeking approval from FDA - after the new rules.
It would not be bad to 'be approved before Novo Nordisk - in the fight against one of the worst diseases that can affect humans.
What is the 'real reason' for where AMRN is in the market:
https://www.findlaw.com/litigation/filing-a-lawsuit/can-i-sue-a-judge-.html
Ziploc, Agree with your historical facts - of what actually happened - all the way Zip'.
------------------------------------------
No easy task to turn this ship around - what the current SP reminds us every day. I still trust though - it 'can be done'.
At least new leadership 'getting spending under control' - as a result of Proxy fight - has given the Company a couple of years ekstra of years to start revenue 'for real' outside the deeply unfair competition (build on fraud) in the USA.
Sleven, Great find. Super article with a serious number of highly respected Pros in their fields behind the very thorough article.
Under here eg about the mo-dispute;
North, Got it . Thanks 🙂
North, Where can I se SP of - BIGT (The Roundhill BIG Tech ETF) - Yahoo seems frozen november 8 - 2023 ?
(Current SP is 32.78) - but where to follow the ETF ?
-------------------------
Here my own broker - just found this right now 🙂
https://www.nordnet.dk/markedet/etf-lister/18021278-the-roundhill-big
DAR53, Thanks' - I'll go with that perception until someone tells us otherwise 🙂
JR, Thanks' for your effort - in trying to understand / explain what is going on around the 'official' drop in Sarissa holding of AMRN shares from 24 - to now 10 mill shares 🙂
Goldman dont like AMRN much.
https://stockanalysis.com/stocks/amrn/forecast/
Tried to dig into why Sarissa now only 'officially' hold 10 mill shares - did not find any explanation anywhere ?
If anyone know what it is about - please share :)
RT Vegas, So this were your Black Week investment - difficult not to get tempted by all you can save 🙂
Sleven, Thanks - reads like 'full speed Europe' 🙂
I do agree with a number of posters here - Brave will not move the needle much 'day one' - even the results may be great.
What it will do (which is deadly important) - is add to chances of serious BP interests for taking over the company (BO).
--------------------------------
Hard to believe today the euphoria - surrounding Amarin weeks after release of the R-I results september 2018. The SP jumped 400% on day of release - and kept rising for weeks there after ending above $26 - before reality set in.
Sleven, Thanks - not often that happens 🙂
But it is in fact sad - you have this layer of nonproductive parasites making fortunes - in a business that is supposed to be about helping people. That I think most people can agree on.
Sleven, As the 'king of facts' - a bit surprised - you obviously dont know how drugs are distributed through 'wholesalers / middlemen' - nearly ALWAYS - in USA:
https://www.ftc.gov/news-events/news/press-releases/2022/06/ftc-launches-inquiry-prescription-drug-middlemen-industry
https://www.commonwealthfund.org/publications/issue-briefs/2022/jul/impact-pharmaceutical-wholesalers-drug-spending
https://healthpolicy.usc.edu/research/flow-of-money-through-the-pharmaceutical-distribution-system/
https://www.thepharmaletter.com/article/intermediaries-capture-41-of-price-paid-for-drugs-in-usa-study-shows
https://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-hda-role-of-distributors-in-the-us-health-care-industry.pdf
https://content.naic.org/cipr-topics/pharmacy-benefit-managers
----------------------------------------------
The cynical parasites are everywhere in this industry - supposed 'to help the sick' !
The media awareness is getting better. Still not world class - but improving 🙂
We're thrilled to congratulate our partners, Eddingpharm, who have received confirmation that China’s NMPA has accepted its marketing application for a potential Cardiovascular Risk Reduction (CVRR) indication for VASCEPA (icosapent ethyl).
— Amarin (@Amarincorp) November 16, 2023
JHC, You are truly acting like a sick stalker when it comes to - spending your day (and night) throwing endless lying crap about Alex Denner on Finance Boards. That is obsessed pathetic behavior.
You obviously have no idea how a business (any business) is run.
Alex Denner is not even on the Board of Amarin - and has nothing to do with how the company is run - day to day.
---------------------------------------------
Where Amarin is today is a result of Nevada Judge Du - removing the entire foundation that Amarin were built on. Erasing the 6 patents that it took Amarin 10 years and +100 million dollars in FDA required trial - thrown overboard in one court ruling 'based on fraud' - is why SP are where it is today.
---------------------------------------------
According to market experts - what we all 'as retail investors' achieve - with Sarissa takeover is' - that the now fully control of money spent - gives the Company a couple of more years to 'turn the ship'.
Rather simple to understand really.
Capt, And you did 'nt even mention the very likely effekt in preventing / diminishing risk of dementia / AZ for big groups of population.
Even the uncertainty around APOE-4 gene holders - this is only round 25% of populations - the other 75% has already been proven to benefit in less risk of dementia diseases - taking Vascepa.
And what do we actually know on longtime 'sideeffekt of the weight loss drugs .
My son who have been digging somewhat into the late (gigantic) NOVO success with the weight loss drugs - told me:
What Novo forgets to tell patients from the start is - 'you have to keep taking the medicine' or you will just regain the weight loss - quickly again'.
Trees don t grow into heaven - not even for NOVO - even though 'they can almost touch the money heaven' these days - with the insane succes of their weight loss drugs 🙂
north, I were looking for LLY - and the Cleveland link appeared - from yesterday november 12 - so I thought this at least related to what you mentioned 🙂
And of course this is rather wild article if the data holds water.
Will it damage Amarin - I don really know ?
Where we are how much worse can it get. Many long retailers have lost fortunes on the Amarin stock - and still no light in sight end of the tunnel !
----------------------------------
It gets all the time harder to deny the development after Sarissa takeover have been - the nice version - very disappointing. Where we are now in SP were NOT what any of us expected with new leadership in place.
Amarin's evil spirit #2 after - winner - Nevada Judge - is back 'in the game' - with his usual modest way of presenting:
The news from Amarin following AHA 2023:
We’re excited to be on the ground in Philly for this year’s #AHA23. Throughout this weekend exciting new data has been released - including the results from our latest REDUCE-IT® prespecified subgroup analysis in patients with Metabolic Syndrome, but without diabetes at baseline.
— Amarin (@Amarincorp) November 12, 2023
Weekend - Only one number comes to mind.
So sad human race on this planet haven't moved one bit since middle ages.
BBI, Dont know you got to that conclusion ?
There is in fact lots of applyers for the jobs 🙂
Under here a couple of examples:
ORBAPU, I do in fact agree with you - in the end - 'EVERYTHING' - or Close - is about money these days .
And actually (as you implie) Pharma business 'in general' could be seen as the most cynical of all' - making even 'more money' - on drugs for 'known side effects 🙂
--------------------------
Where are Longs investing in Amarin - here nearing end of 2023 ?
Personally I feel a lot better (than after DuSaster happened 2020) - that we now have a team of specialists in handling a troubled 'undervalued' small Bio Company in control of Amarin.
This give the many long investors a 'real chance' of a - 'if not direct profit' - at least a less painful economic ending 🙂
lizzy, Actual rise in revenue for a change 🙂
Laurent, Pdude, An input from a non med / bio person - following the debate on AZ closely - as know the symptoms all to well from close relatives.
-------------------
A thought from the sideline:
The most high risk people for getting the disease has been established is the double APOE4 holders.
But not all double APOE4 get it - right. That to me (if I were a researcher / scientist) would make ' looking at those high risk people' - very interesting.
Establishing - Why do these individuals at high risk 'Not get the feared disease'. What separates them from - the group that does ???
That would seem a logical plan to - try to break the code of one of the most feared diseases on the planet.
---------------------------------
Ok - likely some of the pro people working to solve this probably 'most researched' disease on this earth right now - had the same thoughts 🙂
Knowledge of the gene related factor in developing dementia / AZ - has been know for quite some time.
Here an article from 2016 on the subject - that again has the EPOE-e4 as a central factor of the decease.
Rose, I saw here on this board - yesterday (to tired to look which poster) - that only 6.000 out of 750.000 doctors in the USA - recommend / prescribe Vascepa.
--------------------------------------------
As of right now - even Vascepa - 'Guaranteed' - would prolong lives of 30- 50% of US citizens - with likely 8 - 10 years minimum - only very limited number of doctors actually know that.
Lack of 'telling people' (advertising - commercials) stops the message getting out. Fact is right now - only below 1% of US doctors actually prescribe Vascepa for their patients
-------------------------------------------
Turning that information 'positive' - it leaves a lot of room for Sarissa and Amarin for improvement - also in the USA 🙂
Startet by North mentioning the importance af the APOE-C4 gene - in determining AZ risk - a lot of new informations on dementia and AZ causes har been put to the board.
And as a non educated person in these matters - this is nearly all real news for me. The establized big knowledge of genes related to AZ risk is impressive - never heard of that before.
But that raise a logical next question - how do I know (for me and relatives) - if one have the APOE 4 gene er not ?
Found article on how this is tested / established. And do we really want to KNOW - as in the end only a smaller portion of people who has the APOE 4 actually develop AZ in the end:
Mr SB, This is the first time I'v seen EPA's effect on AD published so directly in an official conclusion:
North; Here an article on the genes related to AZ.
https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers-genes/art-20046552
And here the ten risk factors - more on the subject:
https://theconversation.com/the-ten-factors-linked-to-increased-risk-of-alzheimers-disease-143122
LM, A question from a non bio / med knowledgeable person ?
-------------------
Would it be possible (any precedent) to contact participants in the R-I trial - answering questions on their later dementive status ?
A portion will be dead - but R-I status is still only some 5 years away (2018) - the 5 years that have passed, might actually be a positive in this context - of 'following up on the later effect of Vascepa on the brain - in the big group of people.
Recognize that there will be a number of other challenges on the way - (some have stopped taking Vascepa in the meantime etc. ).
But feed the right data, from a group this big (even after eliminating all not statistically relevant participants) - into modern computer calculations - results would be extremely exciting to 'follow' - given the weight of the big double blinded R-I trial.
---------------------
If something like the above presented idea were possible - would be accepted by FDA as 'trustworthy relevant data' - in the fight against AZ and dementia prolems' - it could to some extent 'compensate' (in lack of a better word) - the totally unforseen / meaningless / 'based on fraud' - Judge Du ruling - back in early 2020 🙂